New oxycodone combo aims to curb abuse – first human test underway

NCT ID NCT06500793

Recruiting now Knowledge-focused Sponsor: Ensysce Biosciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests how a new form of oxycodone (PF614) combined with nafamostat behaves in the body. Fifty-four healthy adults will receive single doses to measure drug levels and safety. The goal is to see if this combination can reduce misuse potential while still providing pain relief.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PF614 (oxycodone prodrug) and nafamostat mesylate
What this could lead to: If successful, this could help develop a safer painkiller that reduces abuse potential by combining a prodrug with a blocker.
What could go wrong: This is a very early Phase 1 study in only 54 healthy people, so it cannot prove the drug works for pain or is safe long-term. Side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEER PHARMACOKINETICS

Contacts and locations

Locations

Quotient Sciences
RECRUITING

Miami, Florida, 33126, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.